1 day Ago By ABMN Staff
Shares of Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Get Free Report ) shot up 7.2% during mid-day trading on Friday .
The stock traded as high as $1.95 and last traded at $1.93.
2,157,941 shares changed hands during mid-day trading, a decline of 37% from the average session volume of 3,437,524 shares. The stock had previously closed at $1.80.
Analysts Set New Price Targets PACB has been the topic of a number of recent research reports. UBS Group downgraded Pacific Biosciences of California from a “buy” rating to a “neutral” rating and set a $2.00 target price on the stock.
in a research note on Monday, November 11th. Scotiabank lowered their price objective on Pacific Biosciences of California from $7.00 to $6.
00 and set a “sector outperform” rating on the stock in a research report on Monday, November 11th. StockNews.com raised shares of Pacific Biosciences of California to a “sell” rating in a report on Tuesday, November 12th.
Finally, Piper Sandler increased their price target on shares of Pacific Biosciences of California from $2.00 to $2.50 and gave the stock a “neutral” rating in a report on Monday, November 11th.
One investment analyst has rated the stock with a sell rating, six have given a hold rating and six have given a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $2.
95. Read Our Latest Report on PACB Pacific Biosciences of California Stock Up 10.6 % Hedge Funds Weigh In On Pacific Biosciences of California Several hedge funds and other institutional investors have recently made changes to their positions in the company.
Water Island Capital LLC raised its stake in Pacific Biosciences of California by 91.1% in the 2nd quarter. Water Island Capital LLC now owns 20,000 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 9,537 shares during the last quarter.
Atom Investors LP acquired a new stake in shares of Pacific Biosciences of California in the third quarter valued at about $30,000. Atria Investments Inc lifted its stake in shares of Pacific Biosciences of California by 85.7% in the third quarter.
Atria Investments Inc now owns 21,968 shares of the biotechnology company’s stock worth $37,000 after buying an additional 10,138 shares in the last quarter. Centiva Capital LP acquired a new position in Pacific Biosciences of California during the third quarter worth about $40,000. Finally, Ballentine Partners LLC purchased a new stake in Pacific Biosciences of California during the 3rd quarter valued at about $43,000.
About Pacific Biosciences of California ( Get Free Report ) Pacific Biosciences of California, Inc designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. Read More Receive News & Ratings for Pacific Biosciences of California Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacific Biosciences of California and related companies with MarketBeat.
com's FREE daily email newsletter ..
